Investors could potentially be rewarded with another upcoming catalyst in September with topline Phase 3 MINDSET results, analysts at HC Wainwright noted.
HC Wainwright's Andrew Fein maintained a Buy rating on Axovant's stock and $35 price target based on the company's upcoming results of intepirdine in mild-to-moderate Alzherimer's.
Related Link: Analyst: Neurotrope's Bryostatin-1 Trial Data Justifies Additional Studies
The analyst noted several developments that could "sweeten the deal on the upside" that could improve investor sentiment.
"The clinical pipeline matures with multiple readouts this year even sans MINDSET: HEADWAY-DLB study of intepirdine in 4Q (enrollment completed), phase 2 study of intepirdine on gait and balance, two phase 2 studies of nelotanserin, regulatory discussions for RVT-103, and plans for POC for RVT-104."
The appointment of "biotech superstar" David Hung as CEO serves as not only an "external validation" of the company's prospects but now gives the company ability to better execute on its pipeline.
Axovant remains well-financed with $213 million in cash on the balance sheet which could support its pipeline development in the medium term.
Latest Ratings for AXON
|Feb 2017||Cowen & Co.||Initiates Coverage On||Outperform|
|Dec 2016||Oppenheimer||Initiates Coverage On||Outperform|
|Jun 2016||Leerink Swann||Initiates Coverage on||Outperform|
View More Analyst Ratings for AXON
View the Latest Analyst Ratings
See more from Benzinga
- LendingClub Doesn't Verify Income Data For 66% Of Transactions
- The Inside Story Of How Bill Gates And Microsoft Earned A 400% Return On Comcast
- Callaway Is The Top Golf Brand In The World, But Has Room To Grow
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.